Kanishk Kumar on 2034 Forecasts for aHUS Associated Thrombotic Microangiopathy
Kanishk Kumar, Digital Marketing Executive at DelveInsight Business Research LLP, shared on LinkedIn:
”Atypical Hemolytic Uremic Syndrome Market 2034: Targeting Complement-Mediated Thrombotic Microangiopathy
Atypical Hemolytic Uremic Syndrome (aHUS), a rare thrombotic microangiopathy caused by uncontrolled complement activation, is advancing with novel C5 inhibitors and factor B blockers in 2034.
Delve Insight‘s report covers epidemiology in the 7MM (US, EU4, UK, Japan), market dynamics, and forecasts, projecting significant CAGR from 2020-2034, with ~4,800 diagnosed cases in 7MM in 2023, ~3,500 in US, and adolescents/adults representing ~80% of cases.
Key Developments in aHUS Market:
December 11, 2025: Novartis launched a Phase 3 study of iptacopan in treatment-naive aHUS patients.
December 8, 2025: Alexion Pharmaceuticals, Inc. disclosed a Phase 3b study of eculizumab in Chinese aHUS patients.
Leading Atypical Hemolytic Uremic Syndrome Companies include Novartis, Hoffmann-La Roche, Chugai Pharmaceutical Co., Ltd., Alexion Pharmaceuticals, Inc. , and others.
Promising therapies include Eculizumab, Crovalimab, Iptacopan, NM8074, Ravulizumab, ULTOMIRIS, SOLIRIS, and others.
Delve Insight’s comprehensive report on Atypical Hemolytic Uremic Syndrome Market Insights, Epidemiology and Market Forecast – 2034”
Find the full report here.
Read the full post.

Stay updated with Hemostasis Today.
-
Nov 21, 2026, 20:00Jeyda Star: The FAST Signs of Stroke and the Reality of Life Afterward
-
Nov 21, 2026, 19:59Daniel Lindholm: Women Showed the Largest Improvement in Stroke Risk Over Time in Heart Failure
-
Nov 21, 2026, 19:56Neil Arrowsmith: Raising Awareness of Pulmonary Embolism in Young People
-
Nov 21, 2026, 19:52Muhammad Zeeshan Jamal: Thrilled to Present Our Research on Intermediate-Risk Acute PE in Abu Dhabi
-
Nov 21, 2026, 19:50Mounisha Devireddy: Proud to Share Our Research on High-Risk PE in Pregnancy
-
Nov 21, 2026, 19:47Melissa Hollo: How Severe Anemia Increases the Odds of Acute HF During Pregnancy and Postpartum
-
Nov 21, 2026, 19:44Ashenafi Tazebew Amare: Building Sustainable Systems to Close the Anti-D Immunoglobulin Access Gap in LMICs
-
Nov 21, 2026, 19:43Sheharyar Raza: Interpreting Clotting Times Through Reptilase Time and Thrombin Time Assays
-
Nov 21, 2026, 19:42Minoo Ahmadinejad: Serving on the ISTH 2027 Scientific Theme Committee for Women’s Health